With Clinical Validation Study Complete, Sequenom Moves Ahead with 2012 Launch of T21 Test | GenomeWeb

By Monica Heger

This article was originally published May 5.

Sequenom has completed the clinical validation study for its noninvasive SensiGene Trisomy 21 test ahead of schedule, the company reported last week in a call with investors to discuss its first-quarter earnings.

Sequenom CEO Harry Hixson said that the study's investigators are currently in the process of preparing a manuscript for publication in a peer reviewed journal, after which the test will be commercially launched.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.